High miR-9 levels represent a novel prognostic biomarker to predict development of malignant meningioma

D Baiz, C Negroni, S Ferluga, E Ercolano, C Adams, CO Hanemann

Research output: Contribution to journalConference proceedings published in a journalpeer-review

11 Downloads (Pure)

Abstract

Meningioma is the most common primary tumour affecting the central nervous system; it is classified as benign (WHO I, ~80%), atypical (WHO II, ~15-20%) and anaplastic/malignant (WHO III, ~1-3%). The 3-year recurrence rate in WHO I meningioma is estimated in about 50% and it is much greater in WHO II and III tumours. MicroRNAs (miRNAs) represent a large class of small RNAs driving regulation of gene expression at post-transcriptional level and playing a role in cell proliferation, differentiation, apoptosis and carcinogenesis. Several studies showed that miRNAs are involved in tumour progression and therefore proposed as diagnostic tools. Here, we evaluated miRNAs signature in meningioma to identify novel biomarkers of tumour progression.
Original languageEnglish
Number of pages0
JournalDefault journal
Volume0
Issue number0
Publication statusPublished - 2018
Event25th Biennial Congress of the European Association for Cancer Research (EACR25) - Amsterdam
Duration: 30 Jun 20183 Jul 2018

Fingerprint

Dive into the research topics of 'High miR-9 levels represent a novel prognostic biomarker to predict development of malignant meningioma'. Together they form a unique fingerprint.

Cite this